Dec 11 (Reuters) - AnaptysBio (ANAB.O), opens new tab said on Wednesday it would end the development of its eczema drug after it failed to meet the main and secondary goals of a mid-stage trial.

Eczema has multiple treatments available, including AbbVie's Rinvoq, Pfizer's Cibinqo, Eli Lilly's Ebglyss, Sanofi and Regeneron's Dupixent as well as some generic drugs such as cetirizine.

Dec 11 (Reuters) - AnaptysBio (ANAB.O), opens new tab will end the development of its experimental drug to treat eczema as the treatment failed to meet the goals of a mid-stage trial, the company ...

The clinical-stage biotechnology company said its investigational drug ANB032 didn't meet either ... often referred to as eczema. Atopic dermatitis is a chronic disease that causes inflammation ...

A monoclonal antibody that targets interleukin (IL)-31 receptor alpha, nemolizumab is specifically indicated for individuals 12 years and older with eczema ... with the drug, and the warnings ...

Johnson & Johnson (NYSE:JNJ) enters bearish pattern, death cross, but strong dividends & strategic moves in dermatology ...

The drug, Dupixent, was added to the scheme in 2021 and has been prescribed to almost 20,000 Australians living with severe eczema. Under the PBS, the drug costs patients a maximum of $31.60 per ...

In particular, she cited ongoing phase 3 trials with the topical pan-JAK inhibitor delgocitinib for chronic hand eczema. The FDA accepted the new drug application for delgocitinib for the ...

“Red light therapy is an energy-based modality that uses specific wavelengths of red and near-infrared light (typically 630-850nm) to penetrate the skin and interact with cells,” explains Malik. “It ...